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Rheumatoid arthritis (RA) is a complex autoimmune disease with a poorly understood 
pathogenesis. The disease is associated with polyclonal B cell activation and the production 
of autoantibodies (autoAbs), but there is a longstanding controversy as to whether such 
Abs contribute to, or are secondary to, the pathogenesis of RA. To address the potential 
pathogenicity of human RA–associated Abs, we developed a passive transfer model involving 
mice defi  cient in the low-affi  nity inhibitory Fc receptor, Fc𝗄RIIB. We report that plasma or 
serum from patients with active RA can induce infl  ammation and histological lesions in 
Fc𝗄RIIB−/− mice consistent with arthritis, and that this pathogenic activity is caused by the 
immunoglobulin G–rich fraction. Our results suggest that humoral autoimmunity can 
contribute directly to autoimmune arthritis, and that Fc𝗄RIIB−/− mice are a promising 
model to evaluate the arthritogenic potential of human autoAbs.
Rheumatoid arthritis (RA) is a complex auto-
immune disease distinguished by chronic joint 
infl  ammation that eventually leads to destruc-
tion and remodeling of joint architecture. The 
arthritic histopathology is characterized by the 
presence of leukocytic infi  ltrates composed of 
T and B lymphocytes, macrophages, neutrophils, 
mast cells, and dendritic cells, all of which show 
signs of activation (1). However, it is not known 
what factors trigger the activation and recruit-
ment of these infl  ammatory cells to the joint.
RA is also associated with polyclonal B cell 
activation and the production of autoantibodies 
(autoAbs), but there is a longstanding contro-
versy as to whether such Abs contribute to, or 
are secondary to, the pathogenesis of RA. The 
earliest association of RA with autoAbs was 
the identifi  cation of “rheumatoid factor” (RF) 
present in 60–80% of RA patients (2). How-
ever, not all RA patients are “seropositive” for 
RF and many normal individuals with other 
infl  ammatory diseases produce RF. Association 
of Abs to glucose-6-phosphate isomerase (GPI) 
with RA (3) has also been reported; however, 
this association has been recently challenged 
(4). RA has also been associated with the pro-
duction of IgG Abs against ubiquitous antigens, 
such as keratin, fi  brinogen, fi  laggrin, and cyclic 
citrullinated proteins (CCPs; references 5 and 6). 
Currently it is unclear whether human IgG 
  autoAbs are simply a marker for or are directly 
involved in the pathogenesis of RA.
Animal models have provided convincing 
evidence that pathogenic autoAbs can contrib-
ute to autoimmune arthropathies. In collagen-
induced arthritis models, transient disease can 
be induced by passive transfer of concentrated 
Ig or purifi  ed anti-collagen Abs from arthritic 
mouse donors into naive rodent recipients (7). 
In the K/BxN model (8), arthritis is directly 
attributed to an abundance of IgG Abs specifi  c 
for GPI, which localize to distal joints of mice 
(9), and promotes a cascade of both complement-
mediated and cellular eff  ector events via immu-
nostimulatory Fc receptors (10). Thus, although 
there is excellent evidence supporting the in-
volvement of autoAbs in mouse models of RA, 
major question remains concerning the extent 
to which these fi  ndings can be extrapolated to 
human RA.
To address the potential pathogenicity of 
human RA–associated autoAbs, we developed 
a passive transfer model involving mice defi  -
cient in the low-affi   nity inhibitory FcγRIIB 
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receptor (FcγRIIB−/−). FcγRIIB is a monomeric inhibitory 
receptor that suppresses B cell, mast cell, and macrophage 
activation upon engagement with IgG-immune complexes 
and transmits inhibitory signals via its cytoplasmic immuno-
receptor tyrosine-based inhibitory motif (11). Studies clearly 
show that FcγRIIB−/− mice are hyperreactive to the transfer 
of pathogenic IgG (12, 13). Here, we report that plasma or 
serum from patients with active RA can induce infl  ammatory 
arthritis in FcγRIIB−/− mice, and that this pathogenic activity 
is caused by the IgG-rich fraction. Our results suggest that hu-
moral autoimmunity can contribute directly to autoimmune 
arthritis and that FcγRIIB−/− mice are a promising model to 
evaluate the arthritogenic potential of human autoAbs.
RESULTS AND DISCUSSION
Plasma from a patient with RA (RA1) and a normal donor N1 
were injected i.p. into groups of 8–12-wk-old B6.FcγRIIB−/− 
mice. At this age, there is minimal evidence for lupus-like 
autoimmune disease reported in older B6.FcγRIIB−/− mice 
(14, 15). Mice were injected with human samples on days 
0, 2, and 7 for a total of 2.5 ml plasma per mouse. Plasma 
from RA1 caused mild soft tissue swelling indicated by ankle 
thickness and an overall arthritis score in all (6/6) mice tested 
(Fig. 1, A and C, top). Both hind ankles were aff  ected; how-
ever, the involvement of other joints was diffi   cult to detect 
by simple visual inspection. The joint swelling was transient 
and resolved by day 20. In contrast, none (0/4) of the mice 
injected with control plasma from healthy individual N1 de-
veloped measurable ankle infl  ammation or swelling (Fig. 1, 
B and C, bottom). The transient nature of the infl  ammation 
caused by RA1 plasma is consistent with mouse serum–induced 
models of arthritis that generally result in more severe lesions. 
One explanation for the transient nature of the lesions is ac-
celerated clearance of human Abs in recipient FcγRIIB−/− 
mice. To test this possibility, we monitored the clearance of 
human IgG Abs in mice using mouse sera collected at dif-
ferent time points. Levels of circulating human IgG Abs in 
mice injected with human plasma samples from both RA1 
and N1 were maximal on day 3, followed by a second peak 
on day 8 (Fig. 1 D). The level of human IgG in the mouse 
circulation gradually decreased and disappeared by day 20. 
A similar pattern of IgG degradation was observed in mice 
  injected with plasma from healthy control N1; however, the 
level of circulating human IgGs was signifi  cantly lower at all 
time points compared with that from the RA patient. We 
then tested whether FcγRIIB−/− mice developed a mouse 
anti–human Ab (MAHA) response, which could potentially 
neutralize circulating pathogenic human Abs. Plasma from 
both RA patient RA1 and healthy individual N1 resulted in a 
gradual accumulation of MAHAs after the onset of infl  am-
mation (Fig. 1 E). This temporal pattern suggests that MAHAs 
do not contribute to the lesions and may diminish the patho-
genic activity of the human plasma. Collectively, these results 
provide direct evidence that plasma from a patient with RA is 
able to initiate acute infl  ammatory arthritis when injected into 
genetically susceptible FcγRIIB−/− mice.
To test whether the absence of the inhibitory receptor 
FcγRIIB is necessary for arthritis initiation, age-matched 
B6 mice (n = 3) were injected with the same dose of plasma 
from RA1 (2.5 ml/mouse). As illustrated in Fig. 1 F, no mice 
(0/3) showed joint infl  ammation. This result demonstrates 
that FcγRIIB defi  ciency is required for mice to become sus-
ceptible to arthritis induced by human RA plasma.
Histological analysis was performed to determine whether 
lesions could be detected in the joints of FcγRIIB−/− mice 
Figure 1.  Induction of infl  ammatory arthritis in FcγRIIB−/− with 
plasma from an RA patient. 8–12-wk-old B6.FcγRIIB−/− mice were 
injected with plasma from a patient with RA (RA1) or a healthy blood 
donor (N1) on days 0, 2, and 7. Arthritis was evaluated by measuring the 
increase in ankle thickness and arthritis score (see Materials and methods). 
Each solid line represents the mean ± SEM (mm) results from both ankles. 
Values above the dashed line are considered statistically signifi  cant based 
on measuring the ankle thickness of an untreated control group of 
B6.FcγRIIB−/− mice. (A) B6.FcγRIIB−/− (n = 6) mice were injected with 
plasma from RA1, and the animals were examined for a period of 25 d 
after the initial injection (◆). (B) B6.FcγRIIB−/− mice (n = 4) injected with 
plasma from a healthy blood donor N1 (◇). (C) Representative images of 
hind paws at day 14 after the initial injection with plasma from RA1 (top) 
and N1 (bottom). (D) Clearance of human IgG Abs in the mouse circulation 
during the time course of the experiment. Human blood samples were 
injected on days 0, 2, and 4 as indicated by arrowheads. (E) Accumulation 
of MAHAs was more pronounced in recipients of plasma from RA1 as 
compared with control individual N1. (F) B6.FcγRIIB+/+ mice (n = 3) in-
jected with plasma from RA1 did not develop arthritis when injected with 
the same volume (2.5 ml/mouse) of arthritogenic RA1 plasma.JEM VOL. 203, February 20, 2006  277
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injected with arthritogenic human plasma (Fig. 2). We ob-
served a normal synovial lining, acellular joint space, and 
smooth articular cartilage in the ankle joints of mice (n = 2) 
injected with normal plasma N1 and killed on day 11 after 
initial injection (Fig. 2, A and B). In contrast, the joints of 
mice injected with plasma from RA1 and subsequently killed 
on days 11, 14, and 15 (total n = 3) had arthritic lesions. The 
mouse killed on day 11 had marked infl  ammation within the 
joint space and subsynovial tissues (Fig. 2, C and D). Mild sy-
novial hyperthrophy and hyperplasia were present; however, 
the bone and articular cartilage were unaff  ected. The arthritic 
lesions were characterized by large numbers of infl  ammatory 
cells, predominantly neutrophils with some macrophages and 
a few lymphocytes (Fig. 2 D). The mice analyzed on days 14 
and 15 (n = 2) had edema of the periarticular soft tissue as 
well as mild synovial hyperplasia and hypertrophy with diff  use 
infl  ammatory cell infi  ltrations (representative images shown 
in Fig. 2, E–H). Within the joint space there was a small 
amount of fi  brin mixed predominately with plasma cells, a 
lesser number of neutrophils, and a few fi  broblasts (Fig. 1, E 
and F). The infl  ammatory infi  ltrates present in the synovium 
contained predominantly lymphocytic and plasmacytic cells 
with a moderate number of neutrophils and a few macro-
phages (Fig. 2 G). In addition, there was multifocal perivas-
cular infi  ltration within perivascular soft tissue that contained 
neutrophils, macrophages, and a few multinuclear giant cells 
(Fig. 2 H). These results provide direct evidence that plasma 
from an individual with active RA contains pathogenic com-
ponents able to initiate acute infl  ammatory arthritis.
To determine whether the ability to promote infl  am-
matory lesions is consistent among RA sera, serum samples 
obtained from three additional RA patients were tested 
  (Table S1, available at http://www.jem.org/cgi/content/
full/jem.20051951/DC1). Patients were classifi  ed as having 
RA on the basis of the American College of Rheumatology 
criteria (16). Groups of FcγRIIB−/− mice were injected with 
sera collected from three additional RA patients (RA2, RA3, 
and RA4) and three healthy blood donors (N2, N3, and N4) 
using the same injection protocol. Once again, we observed 
moderate severity and onset of arthritis in mice injected 
with the pathogenic sera from RA patients (Fig. 3, A–C, 
and   Table S2, available at http://www.jem.org/cgi/content/
full/jem.20051951/DC1), but not with sera from three ad-
ditional normal blood donors (Fig. 3 D and Table S2).
Patients with RA demonstrate hypergammaglobulinemia 
with a wide range of RA-associated autoAbs. Therefore, we 
wanted to determine whether RA-related autoAbs were pres-
ent in human blood samples collected from the RA patients 
and healthy controls. The total concentrations of IgG were 
variable in the samples obtained from the RA patients as well 
as healthy controls (Fig. 4 A). The IgG isotype ratios of sera 
obtained from both RA patient and healthy control groups 
were similar (Table S3, available at http://www.jem.org/
cgi/content/full/jem.20051951/DC1). Of the RA-associated 
Abs tested, anti-GPI Ab was more prevalent in plasma from 
RA1, yet there was no diff  erence in the level of this autoAb 
in the other three RA patients in the cohort as compared 
with healthy individuals (Fig. 4 B). Anti-CCP Abs were el-
evated in three out of four samples from RA patients (Fig. 
4 C) and was not detected in sera obtained from healthy 
Figure 2.  Histopathology of ankle joints. (A) Hematoxylin and eosin–
stained tissue sections from the ankle joint obtained from a representa-
tive B6.FcγRIIB−/− mouse injected with plasma collected from healthy 
individual N1 and killed on day 11. For orientation: s, synovium; b, bone; 
c, cartilage. (B) Higher magnifi  cation of selected area from A showing 
a normal joint space, smooth arthricular cartilage, and normal synovial 
membrane. (C) Section of ankle joint from a mouse injected with plasma 
from RA patient RA1 and killed on day 11 after the initial injection. Note 
the marked expansion of the synovial stroma by infl  ammatory cells. 
(D) Higher magnifi  cation of the synovium shows the infi  ltration with 
infl  ammatory cells is predominantly neutrophilic. (E–H) Representative 
images of the ankle joint from mice injected with plasma from RA1 and 
killed on days 14 and 15. (E) Infl  ammation and synovial hypertrophy are 
seen on day 14, which coincides with the peak of ankle swelling. (F) 
Higher magnifi  cation of a fi  eld from E showing fi  brillation of the cartilage 
surface (arrow) and mixed infl  ammatory cells, predominantly neutrophils, 
and macrophages within the joint space. (G) Mild focal synovial hyperpla-
sia. (H) Periarticular soft tissue with perivascular infl  ammation predomi-
nantly containing neutrophils, macrophages, and a few Langerhans-type 
multinucleated giant cells (arrow). Bar, 100 μm.278  HUMAN ANTIBODIES INDUCE ARTHRITIS IN MICE | Petkova et al. 
donors. All RA patients and one normal donor (N2) were 
positive for IgM RF (Fig. 4 D), and all four arthritic patients 
and two of the normal blood donors (N1 and N4) were IgG 
RF+ (Fig. 4 E). Although there was considerable variation 
in autoAb levels among the RA and normal donor sera, the 
anti-CCP and IgM RF correlated best with the potential to 
induce infl  ammatory arthritis in mice.
Plasma from RA patient RA1 and healthy blood do-
nor N1 was fractionated into IgG+ and IgG– components 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20051951/DC1), and their disease-inducing capacity 
was tested in FcγRIIB−/− mice (Fig. 5). The IgG+ fraction 
obtained from RA patient RA1, but not the IgG– fraction, 
was capable of provoking arthritis in FcγRIIB−/− recipient 
mice (Fig. 5, A and B). At this concentration (total of 47.4 mg 
IgG/mouse), the potency of the IgG+ fraction was similar to 
whole plasma with the same relative IgG concentration 
in the starting volume (Figs. 5 B and 1 A). Furthermore, 
when IgG– and IgG+ fractions were combined and injected 
(Fig. 5 C), mice developed arthritis with the same arthritic 
lesions as IgG+ (Fig. 5 B) and the whole plasma group (Fig. 
1 A). In contrast, mice injected with IgG-bound (14.7 mg 
IgG/mouse) or unbound IgG fractions (<0.0001 mg IgG/
mouse) from nonarthritic donor N1 did not show any 
infl  ammation even when IgG concentrations three times 
(44.1 mg IgG/mouse) above that obtained from normal N1 
plasma were used (Fig. 5, D–F). IgG– and IgG+ fractions 
from one additional patient with established RA were puri-
fi  ed and injected into FcγRIIB−/− mice (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20051951/DC1). 
Once again the IgG+ but not IgG− fraction was able to in
duce mild and transient arthritic lesions in mice.   Collectively, 
these results suggest that the pathogenic component of the 
human plasma leading to induction of arthritis in mice re-
sides in the IgG fraction.
To date, few studies have documented the successful pas-
sive transfer of arthritis into mice by injection of purifi  ed hu-
man IgG Abs. Transfusion of peripheral leukocytes, lymph 
node cells, and plasma from patients with RA into nonrheu-
matoid human recipients failed to provoke any evidence of 
rheumatic disease (17). Other experiments included injections 
of a patient’s own IgG Abs into one knee and an identical dose 
of rheumatoid IgG into the other (18), resulting in RA serum–
induced infl   ammatory reactions persisting for several days. 
Figure 3.  Passive transfer of arthritis with sera obtained from 
three additional RA patients. FcγRIIB−/− mice were injected with sera 
from three additional arthritic patients (RA2, RA3, and RA4; A, B, and C) 
and three normal blood donors (N2, N3, and N4; D). Ankle thickening 
(mm) ± SEM and arthritis score are shown. Results for each group of 
mice were calculated as an average based on individual measurements of 
both hind paws of each individual mouse. The severity and onset of ar-
thritis after injection with human RA samples varied among recipient 
groups; however, a 100% incidence was observed in each group (A, n = 2; 
B, n = 4; C, n = 2). None of the animals injected with sera from normal 
blood donors (A, n = 1; B, n = 3; C, n = 3) developed ankle swelling.
Figure 4.  Levels of human IgG Abs. (A) Total IgG (mg/ml). (B) Anti-GPI 
Abs (OD, 405 nm). (C) Anti-CCP IgG Abs (relative units, RU/ml). Values >5 
RU/ml were considered positive. Mean ± SD is indicated. (D) IgM RF (val-
ues ≥20 RU/ml are considered positive). (E) IgG RF of each blood sample 
obtained from RA patients and healthy controls. Data indicate the calcu-
lated ratios, and values >1 were considered positive.JEM VOL. 203, February 20, 2006  279
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In 1984, Wooley et al. (19) reported that purifi  ed anti–type II 
collagen IgGs from a patient with seronegative rheumatoid-
like arthritis induced mild, transient arthritis in 20–25% of the 
injected collagen type II–susceptible mice. To our knowledge, 
there has been no further documentation of the reliable induc-
tion of arthritic lesions in mice after transfer of human Abs. 
Therefore, despite the presence of autoAbs in many patients 
with RA and related arthropathies, their importance in auto-
immune pathogenesis remains uncertain.
We used a mouse model sensitized by a defi  ciency in 
Fc receptor FcγRIIB to exaggerate humoral immunity as a 
bioassay to investigate the pathogenic activity of human RA–
associated Abs. Our data show that (a) plasma or serum col-
lected from individuals with active RA was able to initiate 
infl  ammatory arthritis in B6.FcγRIIB−/− mice with patho-
logical features of human RA; (b) the infl  ammatory lesions in 
recipient animals are mild and transient in nature but highly 
reproducible; (c) the pathogenic component of the human 
plasma from RA1 leading to induction of arthritis in mice 
resides in the Ig fraction.
These studies suggest that human Abs from RA patients 
can infl  ict pathological lesions consistent with the underlying 
RA syndrome. Although too limited to establish an actual 
link between human-specifi  c autoAbs and RA, they raise the 
intriguing possibility that the FcγRIIB−/− mouse model can 
be used as a bioassay to thoroughly evaluate the pathogenic 
involvement of humoral autoimmunity in RA. In contrast 
to mouse anti-GPI and anti–collagen type II Abs, the speci-
fi  cities of human Abs playing a role in the pathogenesis of 
RA are poorly defi  ned. In particular, Abs that react with one 
or more ubiquitous normal protein (e.g., GPI) show poor 
association with human RA, whereas Abs reactive with 
citrullinated proteins show better correlation (20). It remains 
to be demonstrated whether anti-CCP, or other undefi  ned 
autoAbs, are responsible for the infl  ammatory lesions we 
observed. Our studies suggest the FcγRIIB−/− mouse system 
can be used productively for evaluating the pathological po-
tential of currently known and novel RA-associated   human 
Abs. Conceivably, the same model also could be used to 
evaluate Abs associated with other human autoimmune disor-
ders. Finally, this model has a potential application as a disease 
model for examining novel anti-autoimmune therapies.
MATERIALS AND METHODS
Human samples. Blood samples (serum or plasma) from healthy donors and 
RA patients were collected at The Jackson Laboratory, the Mount Desert 
Island Hospital, or the Rheumatology VA Medical Center at the University 
of New Mexico. All the RA patients enrolled in the study were diagnosed 
and selected for investigation according to the American College of Rheu-
matology 1987 classifi  cation criteria.
Mice. B6.FcγRIIBtm1Rav mice were originally obtained from Taconic 
Farms. 8–12-wk-old male and female B6.FcγRIIB−/− and B6.FcγRIIB+/+ 
control mice (The Jackson Laboratory) were used in the experiments. These 
mice were bred and maintained in an environmentally controlled, specifi  c 
pathogen-free facility in accordance with the guidelines of the Institutional 
Animal Care and Use Committee.
Serum transfer and arthritis scoring. To induce arthritis in experimental 
mice using human sera or plasma, each experimental mouse was injected i.p. 
with 0.5 ml of human sample on day 0, followed by two more injections on 
days 2 (1 ml/mouse) and 7 (1 ml/mouse). Ankles were inspected for infl  am-
mation and erythema by two observers. Joint swelling was assessed by mea-
suring the lateral diameter of the ankles as described previously (21, 22). 
Both ankles were measured three times and the results for each time point 
were presented as average ankle thickness. Delta ankle thickness (mm) was 
calculated based on ankle thickness before the injection with human samples. 
An overall arthritis score was determined by examination of ankles as follows: 
0, unaff  ected; 1, erythema; 2, swelling of one hind limb; 3, severe swelling 
of both hind limbs.
Histology. Whole ankle joints were fi  xed in Bouin’s solution, decalcifi  ed, 
and subsequently embedded in paraffi   n wax. 7-μm serial longitudinal sections 
were prepared from tissue blocks and stained with hematoxylin and eosin. 
Results were interpreted by two qualifi  ed observers in a blinded manner.
Ab detection. Total human IgG and IgG isotype Abs were measured by 
ELISA using unlabeled mouse anti–human IgG Abs (IgG, IgG1, IgG2, IgG3, 
and IgG4) to coat and mouse anti–human IgG (Fc) Ab conjugated to alkaline 
phosphatase (SouthernBiotech) as the detection Ab. Data are expressed as 
concentration of IgG (mg/ml) based on interpolation to a titration of puri-
fi  ed human IgG standards (Sigma-Aldrich). Anti-GPI IgG Abs were de-
tected by ELISA using rabbit GPI (Sigma-Aldrich) for capture as described 
previously (22). Anti-CCP Abs were detected using an anti-CCP ELISA kit 
(Euroimmun US). Anti-CCP Abs were considered positive when the absor-
bance was higher than 5 RU/ml based on a reference sample provided by 
Figure 5.  Induction of arthritis with purifi  ed human IgG Abs from 
patient RA1. Groups of FcγRIIB−/− mice (n = 3 each group) were in-
jected with protein G column–separated IgG– and IgG+ fractions of 
human blood samples. (A, B, and C) IgG– (<0.0001 mg IgG/mouse), 
IgG+ (total 47.4 mg IgG/mouse), and recombined IgG– plus IgG+ (47.4 mg 
IgG/mouse) fractions from RA1 were tested for their ability to induce 
arthritis in FcγRIIB−/− mice. Arthritis was monitored as ankle thickening 
(presented here) and the overall arthritis score (not depicted). (D, E, and F) 
IgG– (<0.0001 mg IgG/mouse), IgG+ (14.7 mg IgG/mouse), and 3× IgG+ 
(44.1 mg IgG/mouse) fractions obtained from N1 were injected in animals, 
and arthritis was monitored for 25 d.280  HUMAN ANTIBODIES INDUCE ARTHRITIS IN MICE | Petkova et al. 
the manufacturer. IgG RF and IgM RF were evaluated using test kits and 
protocols provided by the manufacturer (Euroimmun US). IgM RF values 
were computed as RU based on a reference sample provided by the manu-
facturer (values ≥20 RU are considered positive). IgG RF values are com-
puted as ratios of the OD at 405 nm of the patient sample divided by the OD 
of the reference control. Values >1 are considered positive. For detecting 
MAHA, plates were coated with human IgG (Sigma-Aldrich), and MAHAs 
were detected using goat anti–mouse IgG Ab conjugated to alkaline phos-
phatase (SouthernBiotech).
Purifi  cation of human IgG Abs. Human IgGs were purifi  ed from plasma 
using protein G columns as described by the manufacturer (GE Healthcare). 
Plasma, diluted 1:1 in 1X PBS, was separated using an H Trap Protein G 
column. The column was washed with PBS, IgG Abs were eluted in 0.1 M 
glycine HCl buff  er, pH 2.8, and immediately brought to neutral pH with 
1 M Tris-HCL, pH 9.0. The elution profi  le was monitored by measuring 
the absorbance at 280 nm. Detection of human Abs was accomplished by 
using a human IgG–specifi  c ELISA. The peak of bound IgG fraction corre-
sponded to the fi  rst fi  ve fractions after the void volume. The second peak 
represented the IgG-rich fraction. Fractions were then pooled into IgG-de-
pleted (IgG–) and -enriched (IgG+) groups. The concentration of IgG in 
each pool (IgG– and IgG+) was then measured by ELISA. To verify the pu-
rifi  cation of IgGs, 10 μl of untreated plasma and the IgG– and IgG+ pools 
were separated under reducing conditions on a gradient (4–20%) SDS-poly-
acrylamide gel and stained with Coomassie blue staining.
Online supplemental material. Fig. S1 illustrates the SDS-PAGE pro-
fi  le of whole plasma and diff  erent IgG elution fractions, and Fig. S2 shows 
the induction of arthritis with purifi  ed human IgG Abs from an additional 
RA patient. Table SI lists the clinical parameters of the RA patients in the 
study. Table S2 shows the maximum increase in ankle thickness in mice 
injected with human sera, and Table S3 lists the serum levels of IgG isotypes. 
The online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20051951/DC1.
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